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Abstract:
Background:
Selegiline [(-)-deprenyl] is widely used for the treatment of Parkinson’s disease in humans.
Objective:
Time-dependence of tissue distribution of selegiline following per os administration to rats.
Method:
Oral  administration  of  radiolabeled  selegiline  to  rats  resulted  in  a  pattern  of  tissue  distribution  similar  to  that  following
intraperitoneal injection. Analyses were done using both reversed-phase HPLC and also by counting radioactivity in various body
compartments of rats.
Results:
As a consequence of oral administration of 30 mg/kg of selegiline, its level in the stomach was extremely high (179.57 µg/g tissue
through 54.67 µg/g at 15 min to 120 min), that is one magnitude higher than that in the serum level. High selegiline concentrations
were also detected in the lacrimal glands (7.45 µg/g), kidneys (6.87 µg/g), livers (6.01 µg/g) and lungs (3.47 µg/g) after 30 minutes
of application, which were higher than after intraperitoneal injections.
Conclusion:
The relatively high tissue levels remained for 120 min monitoring. Selegiline levels in the brain (1.69 µg/g) and in the testes (1.88
µg/g) were also considerably higher than following intraperitoneal administration during the entire period of observation (15 to 120
min).
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1. INTRODUCTION
Selegiline [(-)-deprenyl hydrochloride] (Fig. 1) is widely used for the treatment of Parkinson’s disease in humans
[1]. It is a specific and irreversible inhibitor of the monoamine oxidase B enzyme when used in therapeutic doses [2 -
4].
Fig. (1). The chemical structure of selegiline (top left) and its metabolic pathway.
Ehringer and Hornykiewicz [5, 6] detected that the dopaminergic tone of the human brain progressively declined
with age and also in certain diseases. This phenomenon is characteristic of Parkinson’s disease. Selegiline exerts its
effect in the dopaminergic system of the brain counterbalancing this decline by multiple mechanisms. Selectively and
irreversibly inhibiting the MAO enzyme, selegiline is responsible for the inhibition of the degradation of dopamine [3],
moreover, selegiline inhibits the high-affinity reuptake of biogenic amines (such as dopamine) [7, 8] and also facilitates
dopamine release from the corpus striatum [9]. Acute selegiline treatment produces either no or only moderate effect
[10]. Following chronic administration, a definite increase in both the dopamine content and the potassium-induced
dopamine release in the brain tissue could be observed [9].
In  addition  to  the  therapeutic  use  of  selegiline  in  Parkinsonism,  its  further  beneficial  effects  have  also  been
published. Knoll, et al. [11 - 13] found an increased life span of rats as a result of chronic treatments with selegiline and
p-fluoroselegiline [14]. Independent research groups [15 - 17] confirmed Knoll’s results, and claimed that longevity of
rats  was  originated from the  inhibition of  oxidative  enzymes by selegiline  [17,  18].  Knoll  and Dalló  published the
positive correcting effect of selegiline and p-fluoroselegiline on sluggish sexual behavior of male rats [14, 19].
Definite incorporation during drug distribution takes place in silent binding sites (such as serum proteins) [20, 21]
and  active  binding  sites,  such  as  receptors  and  various  receptor-like  binding  sites,  such  as  special  sites  including
enzymes [22]. Active binding sites can be the target of drug for drug discovery [23]. The effect of drugs serves to locate
their  binding site(s).  Our recent publications definitely suggested incorporation of selegiline in the brain and testes
following i.p. administration [24, 25]. Similarly, deuterated fluoroselegiline showed incorporation and served for PET
studies  of  monoamino  oxidase  B  in  the  cynomolgus  monkey  brain  [26].  In  pharmacological  experiments  on  the
distribution and metabolism of selegiline, intravenous and intraperitoneal injections are administered in order to avoid
the first-pass effect of the liver. However, the majority of human treatments prefer oral administration to injection if it is
not contraindicated. This paper is devoted to determine time-dependence of tissue distribution of selegiline following
per os administration to rats.
-
-
- -
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2. MATERIALS AND METHODS
2.1. Materials
2.1.1. Chemicals and Solvents
Selegiline hydrochloride (Fig. 1) was the kind gift of Chinoin Pharmaceutical and Chemical Company, Budapest,
Hungary (its recent name is: Chinoin Sanofi-Aventis, Budapest, Hungary). Radiolabeled selegiline (14C-methyl) was
synthetized in the Isotope Institute (Budapest,  Hungary) with a specific activity of 1.851 MBq/mg. Sodium citrate,
disodium phosphate, octane sulfonic acid sodium, Na2-EDTA, hydrogen peroxide and HPLC grade acetonitrile were
purchased from Sigma-Aldrich Kft. (Budapest, Hungary).
Soluene-350 and Optiphase scintillation cocktails were purchased from Perkin Elmer (PER-FORM Hungária Kft,
Budapest, Hungary).
2.2. Animals
Male Wistar rats were supplied by Toxicoop (Budapest,  Hungary) weighing 195 – 205 gram. The experimental
protocol  was  approved  by  the  ethical  committee  of  ANTSz  (Budapest,  Hungary)  with  a  permission  number
1810/003/2004.  All  experimental  conditions  conformed  to  86/509/EEC  regulation.
Rats (in each group n = 3) were orally (per os) treated with 30 mg/kg 14C-labeled selegiline dissolved in saline. The
rats were sacrificed following 15, 30, 60 and 180 minutes of treatment. Blood, CSFs, urine, faeces, the brains, lacrimal
glands, salivary glands, testes, kidneys, livers, lungs, hearts, stomachs, eyes and cochleas were isolated or dissected.
The samples were kept at -80 ºC until analysis.
2.2.1. Sample Preparation
The  samples  were  homogenized  in  0.3  M  of  perchloric  acid  using  Ultra  Turrax  T25  homogenizer  (IKA
Labortechnik,  Staufen,  Germany) at  20,000 rpm for  30 sec at  room temperature.  Homogenates were centrifuged at
14,000 rpm for 20 min at 4 ºC in an Eppendorf centrifuge, (A. Hettich, Tuttlingen, Germany) and supernatants were
used for selegiline determination by RP-HPLC.
Calibration curve was constructed with triple injections of 6 spiked standard samples from 0.1 µg/ml through 5
µg/ml selegiline (Fig. 2). Selegiline levels in the samples were calculated by the mean of the results of triple injections.
Fig. (2). Calibration curve for determination of radioactivity.
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2.2.2. HPLC Determination of Selegiline Content
The  set-up  for  HPLC  was  purchased  from  ABL&E  Jasco  (Budapest,  Hungary).  It  consisted  of  a  JASCO
DG-2080-54 Degasser, JASCO PU-1580 Pump, JASCO AS-2057 Plus Automatic Sample Injector, an Intro EC detector
(Antec, Leyden, the Netherlands), a JMBS Hercule 2000 Chromatography Interface and a Borwin 1.50 Controller and
Evaluation Software.
The  stationary  phase  was  a  Zorbax  Rx-C18  (4.6  mm x  250  mm x  5  µm)  column  purchased  from  Kromat  Kft
(Budapest, Hungary).
The mobile phase was a 2:8 (v/v) mixture of acetonitril: aqueous buffer at pH 3.7, while the buffer was the solution
of 10 g citric acid, 10 g trisodium phosphate, 100 mg OSA, dissolved in 600 ml HPLC quality of water, which was
completed to 800 ml. Temperature of the column was kept at 35 ºC and analyses were done using 1 ml/min flow rate.
An injection volume of 75 μl was applied.
An Intro EC detector using amperometric detection mode at 0.95 V was used and the total range was 2 nA.
2.3. Determination of Radioactivity in Various Samples
2.3.1. Treatment of Tissue Samples
About 100 mg of each liver, brain, lacrimal glands, salivary gland and testes were transferred into 20 ml scintillation
vials. 1.5 ml Soluene-350 was added to each sample, kept at a 60 ºC water bath for 90 minutes and was then cooled
down to room temperature. Afterwards, 0.2 ml of 30% hydrogen peroxide was given in two portions (that is twice 0.1
ml) and was shaken well after each portion. The samples were kept at room temperature for 30 minutes, followed by
keeping at 60 ºC for 30 minutes. After cooling down to room temperature, 10 ml scintillation cocktail was given to each
sample and radioactivity counting was performed after 12 hours in a Beckman LS-5000TA counter. The treatment of
serum and urine samples was similar except that 50 µl of the samples was taken. Moreover, 0.5 ml isopropanol was also
given to the samples following treatment with 30% hydrogen peroxide and provision of the scintillation cocktail.
Fig. (3). Calibration curve for HPLC determination of selegiline.
3. RESULTS
3.1. Calibration for 14C-Deprenyl Content
Calibration curve for the determination of radioactivity is given in Fig. (2).  Fig. (3) gives an HPLC determined
calibration curve of non-metabolized selegiline. Fig. (4) triplet gives a representative chromatogram of selegiline in
testis. Fig. (4a) shows the chromatogram of blank (untreated) testis. Fig. (4b) shows the chromatogram of testis spiked
with selegiline and Fig. (4c) gives the chromatogram of testis from a selegiline-treated rat.
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Fig. (4). Representative chromatograms for HPLC determination of selegiline in testes.
Table 1 provides the results of radioactivity determinations in the tissues and body fluids. Radioactivity is expressed
in  µg/g  or  µg/ml,  based  on  dpm/g  wet  tissue  or  dpm/ml  body  fluid.  Radioactivity  indicates  the  presence  of  the
metabolically intact selegiline plus its major metabolite and the level of (-)-methamphetamine (Fig. 1).
Table 1. Selegiline (and methamphetamine) content of various body compartments of rats following p.o. treatment with 14C-
labeled selegiline. All data are calculated using the calibration curve and from determination of radioactivity.
Tissue or Body
Fluid
Selegiline (or
methamphetamine) level,
µg/ml or µg/g following 15
min
Selegiline (or
methamphetamine) level,
µg/ml or µg/g following 30
min
Selegiline (or
methamphetamine) level,
µg/ml or µg/g following 60
min
Selegiline (or
methamphetamine) level,
µg/ml or µg/g following 120
min
Serum 7.348 3.844 5.123 8.541
Brain 5.842 2.258 2.234 4.266
Cochlea 3.040 3.793 4.825 6.571
Eyes 2.123 1.364 2.850 2.245
Lacrimal gland 15.172 7.617 9.636 19.284
Salivary gland 5.764 3.332 5.080 6.414
Testis 3.264 2.354 2.259 3.923
Kidney 14.461 7.277 6.489 12.392
Liver 49.323 26.842 32.208 81.143
Lung 11.051 4.495 5.282 8.444
Heart 5.678 2.879 2.694 4.978
Stomach 263.229 98.048 106.372 77.322
Urine --- 474.172 90.512 769.814
Faeces 1.240 0.809 0.782 3.727
Table 2 provides the non-metabolized selegiline content of body fluids and tissues of rats on the basis of HPLC
determinations. Triplicate determinations were carried out. The tissue level of selegiline in the stomachs was extremely
high  at  each  sample  (15,  30,  60  and  120  mins)  as  selegiline  was  administered  orally  and  the  decline  during  the
experimental  period  indicates  its  transfer  into  the  ileum.  High  contents  of  selegiline  were  detected  in  the  lacrimal
glands, the kidneys, the livers, and in the lungs at all of the time points detected.
Pharmacokinetics shows the upmost increase of selegiline in the livers, as well as a definite (but moderate) increase
in the lacrimal glands, cochleas and kidneys.
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Table 2. Non-metabolized selegiline content of various body compartments of rats following p.o. treatment with 14C-labeled
selegiline. All data are calculated using the HPLC.
Tissue or Body Fluid Selegiline level, µg/ml or
µg/g following 15 min
Selegiline level, µg/ml or
µg/g following 30 min
Selegiline level, µg/ml or
µg/g following 60 min
Selegiline level, µg/ml or
µg/g following 120 min
Serum 2.06 1.51 1.66 2.20
Brain 1.69 1.45 1.65 1.54
CSF 1.50 1.96 1.64 1.53
Cochlea 1.25 1.18 1.37 1.83
Eyes 1.92 1.85 3.82 5.68
Lacrimal glands 9.88 7.45 3.75 5.22
Salivary glands 2.27 2.49 1.90 2.24
Testis 2.01 1.88 1.86 2.03
Kidney 9.81 6.87 2.48 4.60
Liver 6.61 6.01 2.51 2.33
Lung 4.56 3.47 3.62 3.99
Heart 2.26 1.85 1.89 2.22
Stomach 179.57 76.16 89.69 54.67
4. DISCUSSION
The chemical structure of radiolabeled selegiline (Fig. 1) shows that the N-methyl group contains the source of
radioactivity in the form of 14C. However, the major metabolite of selegiline is methamphetamine which maintains the
radioactivity keeping the 14C-methyl group as well [27, 28].
In Ehrlich's beloved Latin terminology: Corpora non agunt nisi fixata (agents only work when they are bound) [29].
The key–lock principle led to the side-chain theory of antibody formation, which became a cornerstone of the newly-
emerging discipline of immunology recognized by the Nobel Prize. Ehrlich formulated his ideas in chemical terms,
speaking of “chemical affinities” in biological processes (e.g. toxin/antitoxin or antigen/antiserum complexes, “magic
bullets” seeking specific targets). Some three decades of his experience were epitomized in his maxim, “Corpora non
agunt nisi fixata, i.e. a substance is not (biologically) active unless it is “fixed” (bound by a receptor)”. Penetration of
selegiline into the testis is thereby of basic importance from the point of view of MAO enzyme inhibition.
Roberge,  et  al.  [30]  reported  the  dependence  of  activity  of  human  seminal  plasma  on  its  level  of  monoamine
oxidase. As early as thirty years ago, an observation was made according to which the MAO enzyme was present in the
seminal  plasma and  a  higher  MAO activity  was  detected  in  infertile  men than  in  fertile  ones.  Monoamine  oxidase
(MAO) content and activity in the testes show changes during sexual differentiation [31, 32]. MAO inhibitors affect the
copulatory  behavior  of  male  rats  [33].  At  the  same time,  there  is  a  blood-testis  barrier  and its  function is  to  select
penetration of both xenobiotics and endogenous compounds [34 - 37].
A recent publication by Mihalik, et al. [38] claims the favorable effect of selegiline on the increase in the number
and motility of sperms of male rats following chronic intraperitoneal treatment with selegiline.
Pharmacokinetics of orally given selegiline are subjected to the alterating influence of its  first-pass effect.  Oral
administration of various drugs used in humans is generally preferred to any other (i.p., i.v., s.c.) except in the special
cases.  This  is  the  reason  why  oral  treatments  are  carried  out.  However,  pharmacology  can  use  either  i.p.  or  i.v.
administration to avoid the first-pass effect of the drug. This method has been used and reported in our preliminary
publications [9, 24, 25, 27]. However, to monitor the pharmacokinetics related to the use of selegiline in humans, oral
administration  should  be  applied.  Certain  fluctuations  in  the  selegiline  levels  in  the  serum,  brain,  etc.  must  be  the
formation and completion/saturation of the first-pass effect of the liver.
CONCLUSION
A high deprenyl level was found in the stomachs, kidneys, lacrimal glands, livers and lungs after 15 minutes of
administration, indicating the site of absorption as well as the major excretion routes. The relatively constant selegiline
levels  in  the  brain  and  testes  show  the  sites  where  selegiline  is  bound  by  the  monoamine  oxidase  enzyme.  This
interaction can cause an inhibition of this enzyme resulting in an elevated number and motility of sperms.
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